EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence

Shun Wen Chew iD, Jasmine Cheong Zhen Yi, Samuel Lim Jian Rong, Nicholas Yip Zhe Wei, Mohd Shawal Faizal Mohamad, Chim C Lang, Anna-Maria Choy iD

European Cardiology Review · 02.11.2026

DOI: 10.15420/ecr.2025.94 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 02.11.2026. Verfasst von Shun Wen Chew und 6 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Medical School, University of Edinburgh Edinburgh, UK. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy, microvascular dysfunction and chronic energetic inefficiency. Current therapies relieve symptoms or left ventricular outflow tract obstruction but do not directly target these metabolic abnormalities.

Methods

We systematically searched PubMed, Embase, Google Scholar and ClinicalTrials.gov from 1 January 2000 to 31 May 2025 for randomised trials, observational cohorts, registries and case series (≥3 patients) evaluating fatty acid oxidation inhibitors (perhexiline, trimetazidine), late sodium current inhibition (ranolazine) or sodium–glucose cotransporter 2 inhibitors (SGLT2I) in adults with HCM. Outcomes included exercise capacity, diastolic indices, symptoms, arrhythmia burden and safety.

Results

Seven HCM-specific studies met inclusion criteria: trimetazidine (one randomised controlled trial [RCT]), perhexiline (one RCT), ranolazine (one RCT, one real-world cohort and one case series) and SGLT2I (one prospective controlled cohort, one nationwide registry). Most enrolled predominantly non-obstructive or mixed HCM. Trimetazidine had neutral effects on peak VO₂, diastolic function and biomarkers. Perhexiline improved phosphocreatine-to-adenosine triphosphate ratios, diastolic indices, peak VO₂ and New York Heart Association class. Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO₂. In the included HCM studies, empagliflozin/dapagliflozin exposure in a small prospective cohort was associated with improved E/e′ and New York Heart Association class, while broader SGLT2I use in a diabetic HCM registry was associated with lower mortality and hospitalisation for heart failure.

Conclusion

Metabolic modulators and SGLT2I could improve diastolic parameters, symptoms and arrhythmia burden in selected, mainly non-obstructive HCM populations but have not demonstrated consistent gains in exercise capacity. Larger, phenotype-stratified randomised trials are needed to define their role alongside contemporary HCM therapies.

Schlagwörter

Stichwörter der Autor:innen

Hypertrophic cardiomyopathydiastolic dysfunctionmetabolic modulationperhexilineranolazinesodium–glucose cotransporter 2 inhibitortrimetazidine

Autor:innen und Institutionen

  • Edinburgh Medical School, University of Edinburgh Edinburgh, UK.
  • School of Medicine, University of Dundee Dundee, UK.
  • Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre Kuala Lumpur, Malaysia.
  • Division of Cardiovascular Research, School of Medicine, University of Dundee UK.

ORCID-Profile: Shun Wen Chew, Anna-Maria Choy

Zitieren

APA

Chew, S. W., Yi, J. C. Z., Rong, S. L. J., Wei, N. Y. Z., Mohamad, M. S. F., Lang, C. C., & Choy, A. M. (2026). Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence. European Cardiology Review. https://doi.org/10.15420/ecr.2025.94

Vancouver

Chew SW, Yi JCZ, Rong SLJ, Wei NYZ, Mohamad MSF, Lang CC, et al. Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence. European Cardiology Review. 2026. doi:10.15420/ecr.2025.94

BibTeX
@article{Chew2026,
  author = {Chew, Shun Wen and Yi, Jasmine Cheong Zhen and Rong, Samuel Lim Jian and Wei, Nicholas Yip Zhe and Mohamad, Mohd Shawal Faizal and Lang, Chim C and Choy, Anna-Maria},
  title = {Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence},
  journal = {European Cardiology Review},
  year = {2026},
  doi = {10.15420/ecr.2025.94}
}
Kostenlos starten →